Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? by Okeke, Malachy Ifeanyi et al.
viruses
Review
Hazard Characterization of Modified Vaccinia Virus
Ankara Vector: What Are the Knowledge Gaps?
Malachy I. Okeke 1,*, Arinze S. Okoli 1, Diana Diaz 2 ID , Collins Offor 3, Taiwo G. Oludotun 3,
Morten Tryland 1,4, Thomas Bøhn 1 and Ugo Moens 2
1 Genome Editing Research Group, GenØk-Center for Biosafety, Siva Innovation Center,
N-9294 Tromso, Norway; arinze.s.okoli@uit.no (A.S.O.); morten.tryland@uit.no (M.T.);
thomas.bohn@uit.no (T.B.)
2 Molecular Inflammation Research Group, Institute of Medical Biology, University i
Tromsø (UiT)—The Arctic University of Norway, N-9037 Tromso, Norway; diana.k.canova@uit.no (D.D.);
ugo.moens@uit.no (U.M.)
3 Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences
Piaristengasse 1, A-3500 Krems, Austria; collinsoffor57@yahoo.com (C.O.);
graceoludotun@yahoo.com (T.G.O.)
4 Artic Infection Biology, Department of Artic and Marine Biology, UIT—The Artic University of Norway,
N-9037 Tromso, Norway
* Correspondence: malachy.okeke@uit.no; Tel.: +47-7764-5436
Received: 27 September 2017; Accepted: 26 October 2017; Published: 29 October 2017
Abstract: Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary
applications due to its strong safety profile and immunogenicity in vivo. The use of MVA
and MVA-vectored vaccines against human and animal diseases must comply with regulatory
requirements as they pertain to environmental risk assessment, particularly the characterization of
potential adverse effects to humans, animals and the environment. MVA and recombinant MVA are
widely believed to pose low or negligible risk to ecosystem health. However, key aspects of MVA
biology require further research in order to provide data needed to evaluate the potential risks that
may occur due to the use of MVA and MVA-vectored vaccines. The purpose of this paper is to identify
knowledge gaps in the biology of MVA and recombinant MVA that are of relevance to its hazard
characterization and discuss ongoing and future experiments aimed at providing data necessary
to fill in the knowledge gaps. In addition, we presented arguments for the inclusion of uncertainty
analysis and experimental investigation of verifiable worst-case scenarios in the environmental risk
assessment of MVA and recombinant MVA. These will contribute to improved risk assessment of
MVA and recombinant MVA vaccines.
Keywords: Modified vaccinia virus Ankara; orthopoxvirus; hazard characterization; knowledge gaps;
biosafety; environmental risk assessment; uncertainty analysis; smallpox; recombinant vaccines;
virus vector
1. Introduction
1.1. Genetically Modified Viruses (GMVs) for Vaccination
Vaccines and vaccine vectors are termed genetically modified (GM) if recombinant gene
technology is used to create the vaccine or vector. Genetically modified viruses (GMVs) or virus vectors
of homologous or heterologous disease antigens are considered highly desirable for vaccinations
against diseases that are difficult to treat or for which there exists no effective conventional vaccine,
e.g., acquired immune deficiency syndrome (AIDS), malaria, tuberculosis and neoplastic disorders.
Some of the advantages of GMVs in vaccination are the enhancement of immunogenicity without an
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adjuvant and induction of robust cytotoxic T lymphocyte response to eliminate virus-infected cells.
Many viruses have been used as GMVs for vaccination purposes, the major ones being Poxviridae
(Vaccinia virus; VACV), Retroviridae (including lentivirus), Adenoviridae (human Adenovirus; hAdV),
Parvoviridae (Adeno-associated virus; AAV), Herpesviridae (cytomegalovirus; CMV) and Paramyxoviridae
(sendai virus; SeV) [1,2]. Each has unique attributes and associated risks when used as a GM virus
vaccine or vector.
VACV-based vectors have good historical precedence on safety in that VACV and modified
vaccinia virus Ankara (MVA) were used in smallpox vaccination. VACV-based vectors were
also well tolerated in clinical trials, although adverse effects were recorded in some studies at
high dose (over 108 pfu) of MVA [3]. Disadvantages of vectors based on VACV include limited
immunogenicity and pre-existing immunity [4]. Recombinant AdV vectors have the advantage of high
transduction efficiency, a high level of transgene expression, broad cell tropism and the ability to infect
both dividing and non-dividing cells [5]. The AdV vectors are also well tolerated but the presence
of pre-existing anti-AdV immunity is a disadvantage associated with them [6–8]. Similar to AdV,
AAV can infect dividing and non-dividing cells and has broad cell tropism. In addition, AAV vectors
also provide long-term transgene expression, however, they may require host genome integration
for viral gene expression [9]. Retrovirus and AAV vectors provide long-term gene expression and
they are not plagued with pre-existing immunity. However, their package size is limited to 4.5 and
7.5 kilobases respectively [10] and retroviruses are associated with various diseases, e.g., leukemia,
lymphoma and AIDS [11,12]. Vectors derived from SeV show high efficiency in gene transfer and
transduce both dividing and non-dividing cells [13]. SeV infects human epithelial cells efficiently
and can therefore be administered intranasally. This reduces the influence of pre-existing immunity
compared to intramuscular administration [13]. These advantages/benefits of the various GMVs
are being exploited in improving virus-based GM vaccines, while efforts are underway to reduce
their limitations.
1.2. Steps in Environmental Risk Assessment of GMVs
Environmental risk assessment (ERA) is governed by regulatory instruments of different countries
and regions. In the European Union (EU), the ERA is governed by Directive 2001/18/EC [14]
and contains the guidelines and steps (in Annex 1 part IV of the Directive). The Directive
stipulates a stepwise and case-by-case process in which hazards are identified and characterized,
exposure pathways evaluated and potential risks characterized. A routine ERA procedure that is based
on Directive 2001/18/EC involves the following 6 steps: hazard identification, hazard characterization,
assessment of likelihood of hazard and risk level, risk characterization, risk management strategies
and determination of overall risk and conclusion. The aim of the ERA is to assess the risk to humans
and the environment of products derived from genetic modification and to proffer management
and mitigation strategies. The environmental risks associated with GMVs have been widely
published [15–19]. In general, hazards and potential risks to the environment of GMVs are linked
to shedding, survivability, the nature and toxicity of transgenes, the dissemination and transfer
of novel/foreign genes to wild-type viruses as well as contact with, and infection of, non-target
individuals and animals in the environment.
1.3. Poxviruses as Vaccine and Vaccine Vector
Poxviruses have a linear double stranded DNA genome of approximately 130 kbp (seal parapox
virus)–360 kbp (canarypox virus) and their entire morphogenesis is within the cytoplasm of
infected cells. A milestone in vaccinology was achieved when smallpox, a highly lethal disease
caused by variola virus (VARV), a member of the genus Orthopoxvirus and family Poxviridae [20] was
officially declared extinct. Variola major and minor viruses accounted for approximately 30% and
1% mortality [21]. Smallpox is believed to have emerged around 10,000 BC but the origin of VARV is
unknown [22]. Some protection from smallpox was achieved by transferring material from scabs taken
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from smallpox patients to uninfected individuals. “Variolation,” as it was called, resulted in a 2% case
fatality rate but was nevertheless introduced in Europe in the 18th century [23]. In 1796, Edward Jenner
(1749–1823) introduced the principle of vaccination, demonstrating that cowpox virus (CPXV) could be
used to prevent smallpox infection and this quickly gained acceptance [21]. Initially, vaccination was
performed with CPXV [24,25] and later VACV became the vaccine strain of choice. The origin of
VACV remains unknown and is shrouded in mystery and controversy [26]. Smallpox was estimated to
be responsible for 300–500 million deaths world-wide in the 20th century alone [27] and the World
Health Organization (WHO) launched a strategic plan to eliminate smallpox in 1967. Smallpox was
announced eradicated at the 33rd WHO assembly on 8 May 1980 [21]. The successful eradication of
smallpox was possible due to early recognition and diagnosis of the disease, quarantine of patients,
effective vaccination and the fact that VARV infects only humans and has no animal host reservoir.
The discovery that VACV can be used as a vector to express heterologous transgenes in
mammalian cells [28,29], the potential that VARV can be deployed as an agent of bioterrorism [30] and
the increasing zoonotic potential of many orthopoxviruses (OPVs) especially VACV [31], CPXV [32]
and monkeypox virus (MPXV) [33] lead to the resurgence of poxvirus research (especially vaccine
development) after the eradication of smallpox. Recombinant vaccines based on poxvirus are
good candidates for prophylactic and therapeutic vaccination of humans and animals against
infectious diseases and neoplasms [26,34–36]. Poxviruses are suitable as vaccine vectors because
they are thermostable, can infect different hosts and cell types, multiply only in the cytoplasm of
infected cells and have capacity for insertion and expression of up to 25 kbp of foreign DNA as
well as ease of scalability for commercial production. Among OPV-vectored vaccines, only Raboral
V-RG (RVG), a recombinant rabies vaccines based on VACV has been registered. RGV was used to
vaccinate against rabies in raccoons and foxes in North America and Europe [37,38]. Except as an
oncolytic agent, multiplication competent poxvirus vaccines are not recommended for vaccination
(particularly in humans) due to the risk of adverse effects [39,40]. Multiplication incompetent poxvirus
vectors have been developed as a safer alternative to multiplication competent vectors and these
include MVA, attenuated VACV Copenhagen (NYVAC) and attenuated derivatives of fowlpox virus
(TROVAC) and canarypox virus (ALVAC). These multiplication deficient poxvirus vectors form the
backbone of most poxvirus-vectored vaccines that are in preclinical development, clinical trials or
under marketing authorization application (MAA) evaluation [26,41].
1.4. MVA Is a Safe Vector—Need for Hazard Characterization?
MVA is arguably the most promising virus vector due to its capacity to express a wide array of
transgenes with correct post-translational modification and its immunogenicity in vivo along with its
safety profile including host restriction in mammalian cells and attenuation in vivo. Both domestic and
international legislations require that the ERA of virus-vectored vaccines be submitted and evaluated
as part of MAA and clinical trial application. Of particular interest to the ERA is the characteristics of
the MVA vector, its interaction with the host and the environment that may result in immediate or
delayed risk to human and animal health as well as to the environment. The strong safety profile of
MVA-vectored vaccines as well as its history of safe use as smallpox vaccine have stagnated research
into aspects of the biology of the vector that are still poorly understood but also relevant for further
optimization of the safety of MVA. Thus, there is an underlying assumption that MVA is so safe
that studies aimed at risk characterization of the vector is either regarded as irrelevant or has been
unequivocally addressed in scientific literature [42].
Hazard characterization (ERA step 2) of MVA and MVA-vectored vaccines would require
knowledge of: (i) nature and distribution of naturally circulating OPVs that may rescue the MVA
during co-infection and superinfection; (ii) recombination between MVA-vectored vaccines and
naturally occurring OPVs during co-infection/superinfection of cell cultures, immune-competent
and immune-compromised animals; (iii) MVA host restriction in human cells and the molecular
basis for the restriction; (iv) clonal purity of MVA stocks; (v) genome and transgene stability of
Viruses 2017, 9, 318 4 of 29
MVA and MVA-vectored vaccines following multiple serial passages; (vi) virus and host factors that
modulate transgene stability; (vii) effect of the expressed transgene(s) on the virus-host transcriptome,
proteome, metabolome and epigenome and (viii) biodistribution and shedding in immune-competent
and immune-compromised individuals.
The aim of this review is to identify gaps in knowledge with respect to hazard characterization of
MVA vector/MVA-vectored vaccines and highlight ongoing and future experiments aimed to address
these knowledge gaps. This will contribute to a more robust ERA of MVA vector/MVA-vectored
vaccines and further optimization of MVA as a safe vaccine vector.
2. Modified Vaccinia Virus Ankara
2.1. Origin and History of Use as a Smallpox Vaccine
Different variants of VACV were used for vaccination against smallpox. MVA was originally
generated by serial passages of chorioallantois Vaccinia virus Ankara (CVA) in chicken embryo
fibroblast cells (CEF). It was produced in the Bavarian State Vaccine Institute (Germany) during
1968–1985 and used as a human smallpox vaccine [43]. The serial passages (>570 times) of the
virus in CEF cultures resulted in major deletions and mutations in the viral genome, with a loss
of approximately 30 kbp [44]. These modifications also affected virulence and immune evasion
functions [45–47], resulting in a highly attenuated vaccine virus that produced a low degree of adverse
effects on the vaccinees [48]. A complete replication cycle of MVA is restricted to avian cells. In human
and other mammalian cells, the virus replicates its DNA, has unimpaired expression of early and
intermediate genes as well as most late genes but has a block at the stage of virion assembly [34] and
thus cannot produce infectious progeny [49–52]. However, MVA is still able to express viral genes,
including inserted genes (i.e., encoding antigens to which the vaccine is directed) and thus stimulate
the immune system of the recipient in a relevant way.
The MVA vaccine against smallpox was administered mostly intradermally or subcutaneously.
It was often used in Germany from 1968 to 1988 as a first vaccination, usually to vaccinia-naive
children and adults that could be at risk for adverse effects if vaccinated with other and less attenuated
smallpox vaccines [53]. The MVA vaccine elicited a weak virus neutralizing antibody response, as a
first priming of the immune system, which was followed by a VACV smallpox vaccination resulting
in an effective immune response and protection against smallpox. However, it was later discovered
that the weak neutralizing antibody elicited by MVA priming is because the hemagglutinin (HA)
protein to which VACV antibody neutralizing assay is based on is absent in MVA. This is due to the
truncation of the HA promoter [46]. As a response to MVA, vaccinees experienced mild local reactions
such as reddening on the vaccine inoculation site, but did not develop blisters, pustules or ulcers.
Of 7098 vaccinees, 2.3% developed fever (i.e., >38 ◦C) and 4.1% developed non-specific general
symptoms [53]. The MVA vaccine was licensed in Germany in 1977 and was administered to over
120,000 persons. However, these vaccinations were conducted when smallpox was no longer endemic
in Germany and thus its immunological efficacy against a fully virulent VARV remains unknown [54],
but it has proven to protect primates from lethal monkeypox infection [55].
The development and optimization of MVA as a smallpox vaccine continued post
smallpox eradication. This in part is driven by the concern that the smallpox virus may re-emerge,
either due to accidental escape from containment or due to bioterrorism. Hence, there is a public
health need to optimize MVA as an effective but safer alternative to multiplication competent
smallpox vaccines. The European Medicines Agency (EMA) has registered Imvanex® (MVA-BN), as a
smallpox vaccine. MVA-BN is a single clone derived from MVA-584 following six rounds of plaque
purification [56]. Currently, MVA-BN is the most host restricted MVA variant in vitro as well as the
most attenuated in vivo [56].
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2.2. Major Characteristics of MVA
MVA was developed from CVA by over 570 passages in CEF. This resulted in the loss of about 15%
(approximately 30 kbp) of the parental CVA genome [45,46] and several genes coding for host range
factors and immunomodulators are either lost or fragmented [46,57]. MVA is highly host restricted
and undergoes abortive infection in all human and other mammalian cells tested so far, except in Baby
Hamster Kidney (BHK-21) cells [51], rat small intestinal epithelial cells 6 (IEC6) [52] and cell lines
derived from Egyptian fruit bat [58]. However, there is a significant variability in the susceptibility
of MVA strains to mammalian cell lines (Table 1). MVA-1721 productively infects some human cell
lines while MVA-BN undergoes abortive infection in mammalian cell lines (Table 1). Even in some
non-permissive cells as determined by fold increase in virus titer [50], there is limited production of
mature MVA virions [52].
The attenuation of MVA in vivo depends on the strain or variant. Most MVA strains
produce abortive infection in intact animal hosts and have been shown to be non-pathogenic
even in immune-deficient animals and humans [59–62], although some variants were virulent to
immune-deficient mice [56]. Compared to multiplication competent VACVs, MVA induces a more
rapid immune responses and activation of the innate immune system [63].
2.3. MVA as a Vaccine Vector
Following the discovery in 1982 that VACV can express heterologous genes efficiently in
mammalian cells [28,29], MVA has undergone rapid development as a virus vector in vaccines
against infectious diseases and cancers. The unique characteristics of non-productive infection in
human cells [49], attenuation in vivo [56], generation of rapid immune responses [63] and the robust
activation of the innate immune system [64] have positioned MVA as the virus vector of choice.
Although, no vaccine has been licensed for human use, several MVA-vectored vaccines against
HIV/AIDS [65–67], tuberculosis [68], malaria [69–71], Ebola [72,73], influenza [74,75] and hepatitis
B [76] are already in clinical trials, while several candidate vaccines against a plethora of other human
diseases are in pre-clinical trials [26,34,77]. Apart from human infectious diseases, recombinant MVA
vaccines against cancers are in pre-clinical and clinical development [78–81]. MVA is also an
attractive and efficient virus vector for the development of recombinant vaccines against diseases of
domesticated animals and wildlife [82–86]. Although MVA has shown great promise as a vector for
recombinant vaccines, there is still the need to improve its efficacy and safety. MVA is further optimized
for improved vaccine efficacy by deleting the few intact VACV immunomodulatory genes [87–89],
insertion of genes that encodes co-stimulatory molecules [90,91] and more precise regulation of gene
expression from endogenous or synthetic promoters [92–94]. On the contrary, studies aimed at further
attenuation of the MVA vector are miniscule probably due to the assumption that the development
of MVA has reached a satisfactory level of safety and that additional attenuation may compromise
its immunogenicity.
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Table 1. Susceptibility of mammalian cell lines to modified vaccinia virus Ankara (MVA) strains.
Cell Lines Species
Multiplication of MVA Strains and Variants a
References
MVA b MVA-II/85 MVA-VR1508 MVA-BN MVA-B MVA-572 MVA-1721 MVA-574 MVA-LZ
MDCK Canine; kidney SP NP [45,50]
Ederm Equine; skin NP [45]
RO5R Fruit bat Egyptian P [58]
RO5T Fruit bat Egyptian P [58]
RO6E Fruit bat Egyptian P [58]
CHL Hamster Chinese; lung NP [50]
CHO Hamster Chinese; ovaries NP NP [50,52]
BHK-21 Hamster Syrian; kidney P P P P P [47,49–52]
HEK293 Human, kidney NP NP NP NP NP P SP [47,50–52,56]
Hela Human; cervix NP SP NP NP NP P NP SP [45,47,50,51,56,57]
SW839 Human; kidney NP [50]
TK− 143B Human; bone P SP NP NP P [56,57]
MRC-5 Human; lung NP NP NP NP [45,47,57]
FS-2 Human; skin NP [57]
Caco-2 Human; colorectal NP [52]
FHs74int Human; esophagus NP [52]
Hutu-80 Human; small intestine NP [52]
A549 Human; lung SP [52]
HaCaT Human; skin NP SP P [56]
HRT18 Human; colon NP [45]
Hep-2 Human; larynx NP [45]
SK 29 MEL 1 Human; skin NP [51]
LC5 Human; lung NP [51]
85 HG 66 Human; brain NP [51]
U138 Human; brain NP [51]
C8166 Human; blood (T-cell) NP [51]
HUT 78 Human; blood (T-cell) NP [51]
SY9287 Human; blood (B-cell) NP [51]
a Virus multiplication is the ratio of output to input virus titer as defined by Carroll et al. [50]; b All MVA whose strain, variant or passage number was not stated in the relevant publication.
P: permissive, SP: semi-permissive, NP: non-permissive.
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Table 1. Cont.
Cell Lines Species
Multiplication of MVA Strains and Variants a
References
MVA b MVA-II/85 MVA-VR1508 MVA-BN MVA-B MVA-572 MVA-1721 MVA-574 MVA-LZ
MA104 Monkey; kidney P [45]
MIB Monkey; blood (B-cell) NP [51]
BSC-1 Monkey African Green; kidney SP [50]
CV1 Monkey African Green, kidney SP, P P [50,51]
Vero Monkey African Green; kidney SP SP SP SP SP [45,47,50,52]
FRhK-4 Monkey Rhesus; kidney NP [51]
Balb3t3 Mouse; embryonal fibroblast NP NP [56,57]
NMULI Mouse; glandular epithelial SP [52]
AG101 Mouse; skin NP NP NP [56]
DBT Mouse; brain NP [45]
PK(15) Pig; kidney NP NP [50,52]
BEL Pig; lung SP [45]
MDBK Pig; kidney NP [45]
RK13 Rabbit; kidney NP NP NP [45,50,52]
RAB-9 Rabbit; skin NP [50]
SIRC Rabbit; cornea NP [50]
IEC-6 Rat; small intestine P SP [47,52]
H4IIE Rat; liver NP [52]
a Virus multiplication is the ratio of output to input virus titer as defined by Carroll et al. [50]; b All MVA whose strain, variant or passage number was not stated in the relevant publication.
P: permissive, SP: semi-permissive, NP: non-permissive.
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2.4. Priorities for MVA Research: Is Environmental Risk Assessment a Priority?
The MVA vector is generally believed to pose a very low or negligible risk to humans, animals and
the environment [17,19,42]. It is claimed that there is overwhelming and indisputable scientific
evidence [42] to support this assertion. However, such scientific consensus will be undermined if
research on the biosafety and risk characterization of the MVA vector is omitted, not prioritized
or remains unpublished. The number of peer reviewed articles published on the two arms of
MVA vaccine research being: (i) efficacy (immunogenicity) and (ii) biosafety (environmental risk
assessment), was chosen as an indicator of research priority. The object of the PubMed search is
“Modified vaccinia virus Ankara” and keyword(s) were appended to the object as prefix or suffix.
Each pre-fixed or suffixed object was searched independently and the number of published articles
was recorded. PubMed search was conducted on 13 July 2017. When queried with the object “Modified
vaccinia virus Ankara” and “Modified vaccinia virus Ankara vaccine” 866 and 800 articles respectively
were retrieved. Keywords dealing with the efficacy or immunogenicity of MVA returned higher
numbers of published articles (223 to 478), whereas keywords dealing with biosafety or ERA returned
very few hits (3 to 16). When the database was queried with the keywords “MVA safety” instead of
“MVA biosafety,” the number of articles increased from 16 to 183. However, safety studies are not
biosafety or environmental risk studies as they are often misconstrued to be. Safety studies deal with
potential adverse effects on the patient (direct recipient of the MVA vaccine), whereas ERA studies
deal with the evaluation of potential adverse effects to the environment outside of the patient [19].
Since the generic keywords dealing with ERA or biosafety generated very few hits, we expanded
the search by using several specific keywords like “MVA off-target effects,” “MVA genome stability,”
“MVA shedding,” “MVA biodistribution” and others. Again, they returned a very low number of
published articles (0 to 40) with the exception of “Modified vaccinia virus Ankara recombination” which
returned 93 hits. However, except for three articles dealing with recombination in a risk assessment
context [19,95,96], the remainder deal with the construction of recombinant MVA. The PubMed
search demonstrated that there is an enormous data pool on the immunogenicity of MVA but little
peer-reviewed data on its biosafety or ERA.
3. Knowledge Gaps and Omitted Research
3.1. Host Cell Restriction of MVA in Human and Other Mammalian Cells
The inability of MVA to undergo productive infection in human and most cells of mammalian
origin is the main reason why MVA is regarded as a safe virus vector. In approving the licensing of
Imvanex® as a smallpox vaccine within EU, the EMA Committee for Medicinal Products for Human
Use (CHMP) stated, “With regard to safety, the vaccinia virus in Imvanex cannot replicate in human
cells and hence is less likely to cause side effects than previous smallpox vaccines. Imvanex would
therefore be beneficial for people who cannot be given vaccines containing replicating viruses such as
patients with weakened immune system” [97]. The molecular basis for the non-productive infection of
human and other mammalian cells by MVA remains unknown. Thus, this creates a major knowledge
gap in the hazard characterization of MVA. Until the molecular determinant of the host restriction
is identified, it is not a certainty that MVA cannot multiply efficiently in human cells. Earlier suggestions
that the absence of host range genes and the presence of six major deletions in the MVA genome
may be responsible for the severe host cell defect have been shown to be incorrect as: (i) most of the
replication competent VACV host range genes are still intact in MVA [46,98]; (ii) marker rescue of
non-functional host range genes (KIL and C7L) with functional copies did not restore the host cell
tropism of wild-type CVA [45,98]; (iii) marker rescue with large fragments of the CVA genome did
not restore the wild-type phenotype [99] and (iv) most importantly the sequential introduction of the
six major deletions into the CVA genome did not re-create the MVA host restricted phenotype [47].
Thus, the six major deletions and the absence of two VACV host range genes are not essential for the
severe host range defect of MVA.
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Research on identifying the molecular determinants of the MVA host cell defect in human and
other mammalian cells have stagnated presumably because of the belief/assumptions that MVA
cannot undergo productive infection in human cells. At present, the role of insertions/deletions
(indels) and single nucleotide polymorphism (SNP) in MVA non-productive infection of human cells
either singly or in combination with the six major deletions remain uninvestigated. There is also no
attempt to re-adapt MVA to multiply in human cells as a way of understanding the virus and host cell
determinants of host cell tropism. Since MVA host cell restriction in human and other mammalian
cells was achieved by multiple serial passage in CEF, we hypothesized that MVA can be re-adapted to
multiply in human cells by multiple serial passaging in human cell lines. We infected non-permissive
human Caco-2 (ATCC HTB-37) cells [52] with MVA (ATCC VR-1508) at a low multiplicity of infection
(m.o.i.) of 0.01 and blindly passaged it for 40 times. We were able to show 2 to 3 log fold increase in
virus titer from p28 to p40 (Figure 1) and production of mature virions (Figure 2). We were able to
isolate plaque purified MVA variants from p28 to p40 that were able to undergo efficient productive
infection in Caco-2 cells. These observations demonstrate that at least in Caco-2 cells, the host defect of
MVA may be reversible. Alternatively, it may indicate that in spite of over 572 passages and extensive
plaque purification, variants capable of productive infection are still present within the MVA vaccine
stock (ATCC VR-1508). Currently, we are investigating the productive infection potential of these MVA
variants in other human cell lines and primary human cells as well as sequencing their genomes and
comparing it to the non-passaged MVA (ATCC VR 1508). Future work will extend these experiments
with MVA-VR1508 to MVA-BN and examine the attenuation/virulence potential of these Caco-2
productive MVA variants in immunocompetent and immunocompromised in vivo infection models.
The results from these studies will shed light to the host restriction defect of MVA in human cells and
will be of relevance to the ERA of the MVA vector if the results of the in vitro studies are replicated
in vivo.
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Figure 1. Serial passage of Modified vaccinia virus Ankara (MVA) ( TCC VR-1508) in human cell lin .
Caco-2 (ATCC H B-37) cells were infected with purified MVA at a multiplicity of infection (m.o.i.) f
0.01 and the virus was blindly passaged in Caco-2 40 times. At each passage (three days post infection)
infected cells were harvested, freeze-thawed three times and the virus titer was etermined [52].
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3.2. Clonal Purity and Genome Stability f MVA
A robust hazard characterization of a virus vector will demonstrat that the vector is clonally
pure and genetically stable at a passage level and titer that is equivalent to what is present in the
production batch. The MVA vector is assu ed to be homog nous following ver 570 passages in
CEF and subsequent three rounds of plaque purification [100]. The identical genome sequence of
independent MVA strains from at least five independent lab ratories is presented as evidence of MVA
clonal purity and genome stability [42]. However, the next generation sequencing approach used in
sequencing those genomes only reported the genome of the predominant MVA clone or variant, since it
was not designed to determine if minor variants ar present. A demonstration of the clonal purity of
MVA will require deep sequencing of the stock or master seed virus (MSV) in tandem with sequencing
of several MVA clones obtained from the stock follow ng at leas three ro nds of plaque purification.
While Dryvax® vaccine has been shown to be polyclonal using genome wide sequencing designed
to examine if variants are present [101], isolatio and gen me wi e mapping of variants within the
MVA stock or MSV have never been reported. One study employing passage of MVA strains in
immune-deficient mice has shown that the examined MVA strains with the exception of MVA-BN are
polyclonal [56]. However, the observati n from that study showi g MVA-BN to be omogenous can
only be confirmed if MVA-BN is subjected to deep sequencing in combination with genome sequencing
of independent clones isolated from MVA-BN.
Since MVA is subjected to selection pressure (multiple multiplication cycles) during production
of a high titer virus stock intended for vaccination, it is essential to examine the genome stability
of the virus across MSV + 1 to MSV + 5 in human cell lines and in immune-competent and
immune-compromised animal models. At present, this information is not provided in ERA dossiers
submitted for clinical trials or MAA because relevant EU directive (Directive 2001/18/EC) has not
made the provision of such data obligatory. Data on evolution of MVA in permissive cells during
Good Manufacturing Practice (GMP) manufacturing will enable risk assessors to evaluate the genome
stability of MVA and the presence of variants in the production batch intended for vaccination.
The emergence of quasi-species and their role in the modulation of the MVA phenotype including
host range, infectivity, attenuation, virulence and biodistribution is an omitted research field that needs
to be addressed.
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3.3. Transgene and Genome Stability of MVA-Vectored Vaccine
In order to reach the scale required for current GMP of MVA-vectored vaccines intended for
clinical application, the vaccine needs to be amplified multiple times. Such high titer amplification
creates a selective pressure that may result in instability of the recombinant MVA. Instability may
occur within the transgene expression cassette (transgene instability) or outside the expression cassette
(genome instability). Provision of genome sequences of MSV for up to five passages is necessary in
order to evaluate the genome stability of recombinant vaccines based on MVA. However, provision of
whole genome sequences is not mandatory under Directive 2001/18/EC. Thus, the genome stability
of all MVA-vectored vaccines intended for clinical application remains unknown and potential
mutations outside the expression cassette and the phenotypic implications of such mutations go
unreported. Transgene stability of recombinant MVA-vectored vaccine is routinely examined during
hazard characterization. In 2004, our group reported that the influenza virus hemagglutinin (HA)
transgene in some CPXV-MVA recombinants is unstable resulting in the loss of the transgene following
serial passages [95] and southern blot analysis suggested that the HA transgene in the first recombinant
MVA-vectored vaccine is unstable [95]. Other groups have also reported transgene instability in some
MVA-vectored vaccines [102–104]. Transgene stability is essential for robust ERA since the transgene is
the logical tag for tracking the spread of the vaccine virus from target recipients to non-target species.
Consequently, the loss of the transgene may preclude the monitoring of non-target effects from released
or escaped recombinant MVA vaccines.
Studies on viral and host factors that modulate transgene stability are miniscule.
With few exceptions, the effect of transgene insertion site [105–108], promoter choice [104],
promoter spacer length [109], expression levels of the transgene [110], timing of transgene
expression [104], sequence/structure of the transgene/flanking region [111] and host cell used
for virus amplification [96] on transgene stability are poorly understood. Elucidating the virus
and host determinants of transgene instability is essential as such knowledge will be deployed
in designing transgenic MVA vaccines where the probability of transgene instability is extremely
low or negligible. The few studies on transgene stability were done in established cell lines.
To our knowledge, there is no report where transgene instability and the underlying mechanisms have
been investigated in vivo. This is particularly relevant in immuno-compromised infection models.
Immuno-compromised humans, domesticated animals and wildlife are population subsets that may
be exposed to recombinant MVA vaccines, thus the stability of the transgene in immuno-compromised
animal models should be investigated and data obtained should guide the ERA of recombinant MVA.
3.4. Geographic Distribution and Occurrence of Naturally Circulating Orthopoxviruses
The interaction between virus-vectored vaccines and naturally circulating wild-type viruses is
essential to ERA since baseline data on the occurrence, nature and geographic distribution of the later
is required in order to evaluate the potential for recombination, complementation, reactivation or
reversion to wild-type virus. In case of MVA, this will require knowledge of the occurrence,
distribution and characteristics of naturally circulating OPVs in locations and ecosystems in which
recombinant MVA vaccines are to be deployed, especially for the vaccination of domesticated
animals and wildlife. With the exception of Germany [112–116], United Kingdom [115,117,118],
Fennoscandia [119–124], USA [125–128], Brazil [129–132] and India [133–135], data on the occurrence
and characteristics of wild-type OPVs in remaining regions of the globe are limited or non-existent.
MVA-vectored vaccines against malaria [136,137], HIV/AIDS [138], tuberculosis [68], Middle East
respiratory syndrome coronavirus (MERS-CoV) [83], Ebola [73] and several other human and
animal diseases [26,86] are in trials in Africa, Asia and Middle East, but knowledge of the
characteristics and reservoir animal species for wild-type OPVs in these regions are largely non-existent.
Consequently, no scientifically valid inference can be made on the potential of virus-virus interactions
between recombinant MVA vaccines and naturally occurring virus relatives in these regions.
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Even when recombinant poxvirus vaccines are released in areas where some knowledge
exists on the characteristics and occurrence of naturally circulating relatives, no systematic study
has been undertaken post release to monitor the occurrence of potential adverse effect due to
the interactions between genetically modified poxvirus vaccines and naturally circulating OPVs.
Raboral-VRG, a VACV-vectored rabies vaccine [139] was, alongside the attenuated rabies virus vaccine,
successfully used in some regions of Belgium and France during the eradication of fox rabies in western
parts of Europe in a campaign that started about three decades ago. Surveillance programs to monitor
the efficacy of the vaccination (i.e., prevalence of rabies) have been ongoing [140], but no report exists
on the interaction between VRG and naturally circulating OPVs in foxes and other wildlife in Europe.
A comprehensive, genome wide mapping of OPVs in foxes and other animals in the foxes’ food chain
in the regions where the Raboral-VRG bait vaccine has been used would yield data that would help
risk assessors evaluate the potential for recombination, complementation and reversion of the vector
back to wild type. Thus, the absence of data on naturally circulating OPVs before and after release of
recombinant poxvirus (including MVA) vectored vaccines is a significant knowledge gap in the ERA
of MVA-vectored vaccines.
3.5. Recombination between MVA-Vectored Vaccine and Other Orthopoxviruses
Recombination between poxvirus-vectored vaccines and naturally circulating OPVs during
co-infection and superinfection of cells/hosts is significant in terms of ERA. This is because
recombination has the potential of restoring productive infection of a multiplication-incompetent
vaccine-vector as well as generating hybrid viruses with altered host range, cell tropism,
transmissibility and virulence. Although recombination is known to occur among replicating
poxviruses [141–144] and is indeed the method for constructing recombinant poxvirus-vectored
vaccines [145], studies aimed at investigating recombination between MVA-vectored vaccines and
other OPVs are rare. Previously, we have demonstrated that recombination occurred between an
MVA-vectored influenza vaccine and naturally circulating CPXV during co-infection of BHK-21
cells [95] and generated progeny hybrid viruses with parental and non-parental characteristics [95,96].
Provision of data on the potential for recombination between the MVA-vectored vaccine and wild-type
OPVs is not obligatory under Directive 2001/18/EC [14], which may explain the paucity of data
on this issue. At present, the ERA of MVA-vectored vaccine does not evaluate the potential for
recombination between the recombinant MVA vaccine and naturally circulating OPVs because the
risk of recombination is said to be negligible [19]. Recombination between recombinant MVA vaccines
and wild type OPVs is deemed unlikely because MVA does not produce infectious virions in human
and most other cells of mammalian origin [50,52,99] as well as due to repulsion of superinfecting
virions [146–148]. However, abortive infection and repulsion of superinfecting virions are not sufficient
to prevent recombination since recombination requires the presence of homologous DNA only and
repulsion of infectious virions is not absolute but leaky [149]. Although, OPV infections are short-lived,
DNAemia lasting for up to four weeks has been reported for CPXVs [150] and in this time window,
recombination can occur if MVA or recombinant MVA is used to vaccinate such a host. Since DNA
replication is not impaired in MVA during non-productive infection of semi- and non-permissive cells,
recombination between MVA and wild-type OPVs during co-infection and superinfection cannot
be excluded.
To examine the potential for recombination in cells in which MVA multiplies poorly, Vero cells
were co-infected with MVA-vectored influenza vaccine (MVA-HANP) [151] and a feline CPXV
(fCPXV) [119], infected with MVA-HANP or fCPXV respectively and thereafter superinfected with
either fCPXV or MVA-HANP at various times post primary virus infection (ppi). Our results
showed that recombination occurred and that 0.5% of the visual plaques in co-infected cells and
0.4% to 7.1% of plaques in superinfected cells expressed the transgene (Figure 3). Both the transgene
expressing MVA/fCPXV recombinant progenies (Figure 4) and non-transgene expressing MVA/fCPXV
recombinants displayed different plaque phenotypes.
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Cells were co-infected with the parental viruses at a m.o.i. of 5.0 for each virus. Cells were harvested 
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Figure 3. Total and recombinant virus yield in Vero cells. Co-infection, simultaneous infection of cells
with Modified vaccinia virus Ankara-vectored influenza vaccine (MVA-HANP) and feline cowpox
virus (fCPXV); Superinfection 1, primary infection with MVA-HANP and superinfection with fCPXV
at two h ost primary virus infection (ppi); Superi f ction 2, primary infection with fCPXV and
superinfection with MVA-HANP at two h p i; Su fection 3, primary infection with MVA-HANP
and superinfection ith fCPXV at four h ppi; Superinfection 4, primary infection with fCPXV and
superinfection with MVA-HANP at four h ppi; Superinfection 5, primary infection with MVA-HANP
and superinfection with fCPXV at six h ppi and Superinfection 6, primary infection with fCPXV and
superinfection with MVA-HANP at six h ppi. Co-infection and superinfection were done at a m.o.i. of
5.0 for each virus and cultures were harvested three days ppi.
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Figure 4. Plaque formation by hybrid progeny viruses in co-infected and superinfected Vero cells.
Cells were co-infected with t e parental viruses at a m.o.i. of 5.0 for each virus. Cells were harvested
three days post infection, freeze-thawed and sonicated. The harvested cell suspension was used
to inoculate fresh monolayer of Vero cells. Recombinant viruses expressing the influenza virus
hemagglutinin (HA) transgene were detected by standard immunostaining. For superinfection 1,
Vero cells were infected first with MVA-HANP, adsorption was for an h. Medium was removed and
cells were washed twice with cold PBS and then superinfected wi h fCPXV at two h p st primary
virus infection (ppi). In superinfection 2, cells were first infected with fCPXV and superinfected with
MVA-HANP at two h ppi. (A) Vero cells infected with parental strain fCPXV; (B) Vero cells infected with
parental strain MVA-HANP; (C–E), Representative panel of Vero cells co-infected with parental strains;
(F–H) Panel of Vero cells in superinfection 1; and (I–K) Panel of Vero cells in superinfection 2. All panels
show representative fields at approximately 200× magnification.
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These results demonstrated that: (i) recombinant MVA vaccine can recombine with naturally
circulating OPVs during co-infection and superinfection of mammalian cells that are semi-permissive to
MVA and (ii) repulsion of superinfecting virions does not prevent recombination between recombinant
MVA and wild-type OPVs. At present, we are extending these experiments to non-permissive cells
and to immune-competent and immune-deficient animal models, as well as mapping genome-wide
patterns of recombination in the already isolated recombinants. If our results from cell cultures are
replicated in intact animal models, the potential for recombination should be examined for each
MVA-vectored vaccine for which MAA and clinical trial application is being sought. In addition,
the present emphasis on the likelihood or frequency of occurrence but not on the consequences needs a
re-examination. Consideration should also be given to the impact or consequences of a presumably rare
event like recombination. A rare recombination event may generate progeny hybrid viruses that are
more virulent than any of the parental strains. Naturally occurring OPVs like CPXV, MPXV or VACV
may become more virulent if they acquire the transgene encoding co-stimulatory molecules from
an MVA-vectored vaccine following an unlikely recombination event. Among alphaherpesviruses,
recombination between attenuated infectious laryngotracheitis virus vaccine strains resulted in the
emergence of virulent field isolates [152].
3.6. Biodistribution, Shedding and Persistence of GMVs
A vaccine virus/vector will be dispersed to cells, tissues and organs of the patient (biodistribution)
from the initial administration site (e.g., injection site). The virus can be introduced into the
environment via body fluids (e.g., saliva, sweat, urine, feces, nasopharyngeal fluids, blood,
exudates from skin lesions, breast milk and semen of the vaccinee (shedding). Following shedding,
survival of the shed virus/vector outside the host (persistence) will depend on the virus/vector
biological properties and the nature of the environment. Thus, assessment of pathways through
which genetically modified and/or transgenes may interact with the ecosystem (other than the
vaccine recipient) is critical in ERA. In this Section, the relevance of biodistribution, shedding and
persistence of GMVs to ERA is briefly discussed.
3.6.1. Biodistribution
The virus/vector/transgene can potentially be dispersed throughout the body when administered
via a route other than the alimentary canal and this has potential of transmission to sex cells (with the
attendant risk of transmission to offspring). MVA can reach target tissues other than the site of
administration [153,154]. However, being multiplication incompetent, MVA is rapidly cleared from
the tissues [155,156]. In situations where genetic modification has altered tissue tropism of the GMV,
biodistribution will be affected especially for multiplication competent GMVs and this can result in
infection of cells that are naturally not permissive to the original parental virus. This information
is relevant for mapping the dissemination of the recombinant vector. Biodistribution may also
influence the time window and routes of shedding of the virus from the recipient and thus,
the likelihood of transmission to third parties including vertical transmission and transmission
of the vector/recombinant vaccine to other individuals and host species. Further, it is important
to map the biodistribution of the virus/vector/recombinant vaccine in immune-compromised
individuals given that biodistribution in the immune-compromised is expected to differ from that
of the immune-competent individuals. This will provide valuable data on how such recombinant
vaccines may affect those with impaired immune system.
3.6.2. Shedding
The environment is exposed to the virus vector/virus-vectored vaccine if it is shed by the
vaccine recipient. In this case, hospital personnel, caregivers, non-vacinees and others may be exposed
especially if the virus vector is shed via body fluids. When evaluating shedding, the biological
properties of the virus vector/virus-vectored vaccine such as biodistribution, the status of the host
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including immunocompetence, dose and route of administration, sampling frequency and duration
of sampling, methods for sample analysis and data interpretation are important considerations.
In addition, information on the biological properties of the wild-type strain can provide guidance in
shedding evaluations.
Similar to biodistribution, multiplication competence of the virus vector is an important
consideration in evaluating shedding given that multiplication competent virus vector may persist
in the vaccinee for extended periods of time and can increase in amount leading to higher shedding
of infectious particles with an associated likelihood of virus transmission. For such multiplication
competent virus vectors, it is important to analyze their molecular variants, which can also influence
virus shedding. In general, the basic assumptions in the ERA of multiplication competent virus
vectors are that there is a likelihood of spread of the viral vector from the vaccinee into the
environment [157]. Immune status of the recipient can affect shedding, a hazard which becomes
higher when a multiplication competent virus vector is the case under evaluation. If a virus vector is
multiplication incompetent, shedding of the virus is unlikely but evidence should be provided that
in such a case, the protein(s) encoded by the inserted transgene(s) has not altered the multiplication
incompetence of the vector.
3.6.3. Persistence of Virus Vector in the Environment
The ability of the virus vector to survive after being shed by the vaccinee, as well as the stability of
the inserted genetic material in the environment will influence the chance of non-vaccinated organisms
being exposed. Persistence of the most commonly used viral vectors in genetically modified (GM)
vaccines and gene therapy has been discussed in Baldo et al. [18]. Although poxviruses show high
environmental stability, resistance to drying and may remain contagious over a period of several
months in ambient temperature [158,159], they are nevertheless sensitive and easily inactivated by all
disinfectants commonly approved for surface disinfection [160–162].
Persistence of viral particles and DNA in the environment can be affected by several factors
(reviewed in [163]), including the presence or absence of proteolytic microorganisms, lipid and protein
materials serving as protective shields for the virus particles, pH and temperature (freeze-thaw cycles).
Further, presence or absence of DNases, pH and the length of the DNA polymer may affect nucleic acid
persistence. There is dearth of information on persistence of virus-vectored vaccine such as recombinant
MVA outside the host although persistence in different materials of wild-type viruses commonly
employed as vectors is available [163]. Thus, it is often assumed that persistence of GM viruses/vectors
is not different from that of the wild-type strains. This ignores the fact that genetic manipulation
may have affected some biological properties of the GM virus/vector resulting in a persistence that is
different from the corresponding parental virus. An example is where inserted sequences can influence
the genome stability of the viral vector, which can result in an improperly packaged, enlarged and
unstable genome prone to re-arrangement.
3.7. Transmission of Shed Virus Vector and Virus-Vectored Vaccine
In transmission to non-target hosts, persons considered at risk of exposure to virus
vector/virus-vectored vaccine are those that come in close contact with the vaccinee. These often are
family members, health care workers as well as pets and other animals in close contact with the vaccinee.
Knowledge about biodistribution, shedding and the immunological status of the vaccinee close contacts
will help in identifying the route of transmission. If the virus-vector is inadvertently transmitted to
these individuals, clearance should be effective given that a good proportion of the population already
have pre-existing immunity to VACV/MVA. However, should the close contacts have compromised
immunity due to old age, very young, sick or are on immunosuppressive drugs, clearance may
be inefficient and the consequences of infection might be more significant. In these individuals,
interactions (exchange of genetic materials, helper functions of gene products/factors) between GM
virus vector and resident natural viruses could generate quasi virus species that are unstable and
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constantly mutate. This could lead to species with altered epitopes and thus less infectivity [164].
Altered epitope can result in less efficient immune clearance due to weak binding to receptors on the
immune cells and can lead to establishment of chronic, latent or persistent infections. A situation
in which non-neutralizing antibodies facilitate the infection of other cells (antibody-dependent
enhancement of infection) may arise [165,166]. With respect to MVA/MVA-vectored vaccines,
the potential for transmission to non-target hosts is low due to its multiplication incompetence
in most mammalian cells. However, this observation should be demonstrated in vitro in relevant
cell cultures, as well as in both immune-competent and immune-deficient animals for each
MVA-vectored vaccine. This will confirm that multiplication competence has not been restored
in the recombinant MVA vaccine.
3.8. Immune Responses: Implications for Biosafety
3.8.1. Anti-Vector Immunity
MVA is considered a safe vaccine against smallpox. However, animal studies showed that
higher or multiple doses (boosts) are required to obtain the same anti-VACV antibody response as
obtained with a single dose of wild-type VACV [167]. Thus, MVA with higher immunogenicity and
recombinant MVA vectors that elicit improved immune response against the heterologous antigen but
still reduced virulence are needed. VACV encodes several proteins that are involved in evasion of the
host immune response [34,46]. MVA lacks several of these genes and this increases the immunogenicity
of the virus [34,46]. VACV infection in mice and humans induces humoral- (antibody secreting
B cells or plasma cells) and cell-mediated (CD4+ and CD8+ T cell) responses. Because VACV is
used as a vaccine vector, highly attenuated strains such as MVA have been developed. MVA has
retained immune stimulatory properties (see [34] for a recent review). Administration of MVA in
animal models leads to the induction of type I and type II interferons (IFNs), pro-inflammatory
cytokines and chemokines. All are critical mediators of the host anti-viral response. In addition,
virus-specific CD4+ and CD8+ T cell responses are developed, including CD8+ memory T cell
response [34,168,169]. Despite mutations and major deletions, the MVA genome still encodes several
proteins with immunomodulatory functions [46]. Deletion of genes encoding these immunomodulators
can increase the immune response to VACV as demonstrated for A41L and B15R genes. Single removal
of these genes resulted in increased viral-specific CD8+ T cell response and enhanced protection
against challenging with virulent VACV WR in mice [170,171]. Increased immune responses were also
measured after infection with MVA lacking A35R or C12L [87,88]. These studies suggest that MVA
deprived of additional immunomodulatory genes may represent improved vaccine vectors.
The effect of deleting MVA genes in MVA-based vectors expressing foreign antigens on the
immune response against these antigens has also been examined. Deletion of single or multiple MVA
immunomodulatory genes stimulated the immune response against the foreign proteins expressed
by the recombinant MVA mutant [170,172,173]. Alternatively, recombinant MVA vectors expressing
host genes encoding immune stimulating proteins may trigger an increased immune response as was
shown for MVA expressing granulocyte-macrophage colony-stimulating growth factor (GM-CSF) or
C-C Motif Chemokine Ligand 20 (CCL20) in mice [174]. However, in rhesus macaques, high doses of
GM-CSF expressed by MVA/GM-CSF inhibited mucosal antibody response and diminished protection
elicited by MVA/Simian Immunodeficiency virus (SIV) macaque’s vaccine [175].
Reintroducing VACV genes in MVA to modify the immune response to MVA warrant caution
as illustrated by the study of Backes and co-workers [176]. They found that MVA lacking the C7L
gene (MVA-∆CL7) could not prevent phosphorylation of eIF2α, an event important in the antiviral
response mediated by interferons. Reinsertion of the K1L gene, which is involved in NF-κB inhibition
and which is absent in MVA, restored eIF2α phosphorylation, indicating the complementary function
of the K1L and C7L proteins.
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The immunogenicity of MVA cannot only be altered by deletion of immunomodulatory genes,
but also by posttranslational modifications of viral structural proteins. Rojas and colleagues found
that the glycosylation state of VACV particles had an impact on the immune response [177].
VACV naturally activates Toll-like receptor 2 (TLR2), associated with induction of anti-viral neutralizing
antibody response. Deglycosylation of the virus particle blocked TLR2 activation and greatly reduced
the production of anti-viral antibodies, but did not affect infectivity. Glycosylated MVA should
be used to increase the immune response and cause better protection against poxvirus infection.
Vaccination with VACV strains that can multiply in patients with glycosylation defects may result
in poorer immune response and poorer protection against poxvirus infection. Strategies used
to improve the immunogenicity of (recombinant) MVA besides deletion of immunomodulatory
genes include immunization with prime/boost with other viruses or DNA vectors, insertion of
genes encoding co-stimulatory molecules (e.g., interleukins, IFNγ), increased expression of the
foreign antigen (e.g., promoter strength, codon optimization, terminal signal peptide) and adjuvant
(e.g., Glucopyranosyl Lipid A, MF59) (reviewed in [91]. Thus, modulating the expression of MVA
genes in these manners can improve the immunogenicity of MVA vaccines and activate immune
responses to heterologous antigens. However, the effect of these strategies on the biosafety of MVA
including its attenuation, multiplication incompetence, cell and tissue tropism, genome stability,
biodistribution and shedding is mostly not investigated.
3.8.2. Effect of Transgenic Protein on Th1-Th2 Response and Cytokine Proliferation
The Th1 cytokine profile is characterized by IFNγ, Interleukin (IL)-2 and IL-12 production,
while IL-4, IL-5, IL-6, IL-10 and IL-13 are typical for a Th2 response [178,179]. Infection/immunization
with MVA or recombinant MVA can provoke Th1 responses and deletion of MVA genes can further
increase these responses. For example, levels of the Th1 cytokines IFN-γ, IL1B, IL-12 were significantly
higher in mice inoculated with MVA∆C12L/A44L-A46R than in animals challenged with MVA [180].
A higher frequency of IFN- γ, TNF-α and IL-2 secreting E3-specific CD8+ T-cells was observed 8 weeks
after vaccination with MVA lacking B15R compared to MVA [181]. MVA-C, a MVA vector that
expressed the envelope protein and the Gag-Pol-Nef from HIV-1 subtype C induced IFN-γ producing
CD8+ T cells. The number of these T cells was higher upon infection with a mutant lacking the
F1L gene [182]. When genes encoding for co-stimulatory molecules and cytokines are inserted into
the MVA vector in order to improve immunogenicity, evidence has to be provided to show that the
molecules do not predominantly result in a Th2 response. In multiplication competent OPV vectors,
insertion of IL-4 resulted in increased pathogenicity of the recombinant virus [183] due to the inhibition
of Th1 response [184]. At present, provision of cytokine profile data is not obligatory for the ERA of
MVA and MVA-vectored vaccines. However, provision of such a data is important for evaluating the
risk of potential reversion of the MVA vector to wild type.
3.8.3. Modulation of Intracellular Signaling Pathways
MVA not only depends on host pathways to successfully generate its progeny, it must also
counteract inflammatory, innate and acquired immune response pathways that prevent viral
replication [185]. VACV infection resulted in the activation of the Akt signaling pathway [186].
One of the Akt substrates is human cyclic guanosine monophosphate-adenosine monophosphate
synthetase (cGAS). Phosphorylation of cGAS inhibits the production of type 1 IFNs and
inflammatory cytokines, thereby preventing an antiviral response [187]. Hence, VACV triggered
Akt activation helps the virus to evade the host defense mechanism. It is not known whether MVA
infection leads to Akt activation. Another pathway that is modulated upon MVA infection is the
mitogen-activated protein kinase (MAPK) pathway [188–190]. Gedey and colleagues found that MVA
activates ERK1/2 in HEK293T cells [191]. This is in contrast with the findings by Schweneker et al. [188]
who showed that CVA induced sustained ERK 1/2 activation in HEK293 cells but MVA failed to do so.
The authors demonstrated that ERK1/2 activation depended on intact O1L gene; a gene fragmented in
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MVA [46]. The use of different cell lines may explain the discrepancy between the findings of these
studies [188,191]. Infection of Hela cells or mouse embryonic fibroblasts (MEFs) with MVA resulted in
the upregulation of dual specificity phosphatase 1 (DUSP1), a MAPK dephosphorylating enzyme [192].
Infection of DUSP1 knockout mice with MVA enhanced the production of pro-inflammatory cytokines
indicating that DUSP1 is involved in the regulation of innate and adaptive immune responses during
poxvirus infection. VACV activates the MAPKs, c-Jun N-terminal protein kinase 1 and 2 (JNK1/2) [189].
Whether MVA can activate the JNK MAPK pathway was not investigated, but inhibition of this
pathway causes a significant decline in virus yield in BHK-21 cells [189].
4. Future Perspective
4.1. Uncertainty and Uncertainty Analysis
Knowledge is always accompanied by uncertainty. Uncertainty with respect to risk
characterization refers to (i) lack or incomplete knowledge on the likelihood of an adverse effect
occurring and (ii) the lack or insufficient knowledge on the magnitude of the consequences if such
an adverse effect occurred. As we have shown in Section 3, there is insufficient knowledge and data
on some aspects of MVA biology that are relevant to hazard characterization. Thus, at the very least,
there is epistemic uncertainty [193].
Although Directive 2001/18/EC and its supplementary Commission Decision 2002/623/EC
recommend identifying uncertainties and analyzing them during ERA of GMOs and medicinal
products containing GMOs, the ERA of MVA-vectored vaccines (in peer-reviewed literature and
publicly available dossiers submitted to EMA) does not incorporate methodological identification of
uncertainty and uncertainty analysis [194]. On the contrary, knowledge about characteristics of the
MVA vector that are relevant to ERA is presented as determinate [42], implying that uncertainty is
low or negligible [195]. We believe this is a simplification that neither serve the scientific community,
nor the research progress in the field. In risk and crisis communication, it is considered a best practice
to emphasize and acknowledge uncertainty [196]. Hazard characterization of MVA-vectored vaccines
in future should characterize the nature, location and level of the identified uncertainty by employing
uncertainty analysis. Uncertainty analysis using different typologies have already been developed for
genetically modified (GM) plants, chemical pollutants and nanoparticles [194,197,198] and these could
be adapted and applied in the ERA of virus-vectored vaccines including recombinant MVA vaccines.
4.2. Worst Case Scenario
Worst-case assumptions that can be tested and eventually rejected or proven are an essential
sub-step in the risk characterization of GMOs including genetically modified viruses [199] and
plants [200]. The steps used for the ERA of GMVs outlined in Section 1.2 do not have a probabilistic
distribution for the frequency of an adverse effect and the level of consequences associated with
the adverse effect. Rather, the rating of risk as negligible, low, moderate or high is largely based
on weight of evidence (WOE) from peer-reviewed literature and “expert” opinion from scientists
commissioned by regulatory agencies like EMA. Much of the published literature on MVA-vectored
vaccine addresses vaccine efficacy rather than aspects relevant to ERA. Testing for worst-case scenarios
that are falsifiable will reduce uncertainty since a risk analysis where the worst-case scenario is shown
not to occur is evidence that the risk of adverse effect is low. In the case of MVA-vectored vaccines,
assumptions of worst-case scenarios such as recombination with wild-type OPVs and emergence of
more virulent hybrid progenies should be falsified or rejected through experimental investigation in
authentic immuno-compromised and immuno-competent animal models.
4.3. Conclusions
In this paper, we have highlighted the knowledge gaps and paucity of scientific data on key
aspects of MVA biology required for its hazard characterization and presented data obtained in vitro
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on some worst-case scenarios demonstrating that: (i) MVA productively infects human Caco-2 cells
after multiple serial passages in Caco-2 cells and (ii) recombination in vitro between MVA vectored
vaccine and a wild type CPXV in a cell line that is semi-permissive to MVA. Provision of empirical data
to fill in the gaps in knowledge will improve the hazard characterization of MVA-vectored vaccines
resulting in a more robust ERA.
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